Hesperos Inc., of Orlando, Fla., said it increased its human-on-a-chip drug testing capabilities by adding an in vitro, human-human neuromuscular model to its multi-organ microfluidic device systems. Abnormal function of the neuromuscular junction is associated with diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy.